OBJECTIVE: Adipose tissue distribution (visceral vs subcutaneous) has been shown to be an important predictor of insulin resistance, diabetes and cardiovascular disease, independent of body mass index. The beta-2 adrenergic receptor is a major lipolytic receptor in human fat cells and the gene that codes for this protein is an important candidate gene for measures of adiposity and fat deposition. We examined whether two common polymorphisms in codons 16 (Arg16Gly) and 27 (Gln27Glu) are associated with measures of fat distribution in participants of the IRAS Family Study. METHODS: We recruited African-American (AA) and Hispanic-American (HA) families from Los Angeles, CA, USA (18 pedigrees, 272 AA individuals), San Antonio, TX, USA (33 pedigrees, 448 HA individuals) and San Luis Valley, CO, USA (12 pedigrees, 272 HA individuals). We estimated adipose tissue distribution via computed tomography. To test for an association between adiposity measures and these polymorphisms, we used generalized estimating equations, adjusting for age, gender, clinical site (ethnicity), body mass index, and familial correlation. RESULTS: Of the 992 individuals genotyped for these polymorphisms, 57% were female and 15% had been diagnosed with type 2 diabetes mellitus. The mean age was 42.7714.6 y. The Glu27 allele of the Gln27Glu polymorphism was positively associated with (P-value for recessive model): body mass index (0.025), visceral adipose tissue (o0.0001) and visceral-tosubcutaneous adipose ratio (0.009), but not with subcutaneous adipose tissue (0.952). The Arg16Gly polymorphism was not associated with any of the adiposity measures. CONCLUSIONS: These findings suggest that genetic variation in the beta-2 adrenergic receptor gene influences fat deposition and body size in AAs and HAs. In particular, these results support a role for the gene in the distribution of visceral adipose tissue but not subcutaneous adipose tissue.
Introduction
Increased abdominal visceral adiposity has been shown to be a risk factor for insulin resistance and clinical conditions associated with cardiovascular disease, including hypertension and dislipidemia. The evidence suggests that this risk is independent of total adiposity and appears to be a stronger predictor of these diseases than body mass index (BMI). [1] [2] [3] [4] Abdominal visceral obesity is also an important component in the metabolic syndrome, a cluster of lipid and glucose metabolism abnormalities that is characterized by increased systemic levels of inflammatory cytokines and accelerated atherosclerosis. 5, 6 While there is clearly a strong environmental effect on visceral adiposity, there is also evidence that visceral adiposity is subject to significant genetic influence, with heritability estimated at greater than 0.50. 7, 8 The beta-2 adrenergic receptor protein has been shown to play a major role in lipolysis in subcutaneous fat, the body's largest area of fat deposition. 9 Other physiologic actions of the beta-2 adrenergic receptor include increased release of insulin, glucagon and renin, and smooth muscle relaxation. The gene that codes for the beta-2 adrenergic receptor (ADRB2) is an intronless gene located on the long arm of chromosome 5. Several polymorphisms that result in aminoacid exchanges have been identified. 10 The glutamine to glutamic acid exchange at codon 27 (Gln27Glu) and the arginine to glycine exchange at codon 16 (Arg16Gly) are two polymorphisms that are characterized by both evidence for functional relevance and a high degree of heterozygosity. Therefore, these variants are good candidates for having a potential role in complex processes such as obesity and fat distribution and have been examined in a number of such studies. The Arg16Gly polymorphism has been found to be associated with altered ADRB2 protein function, with Gly16 carriers showing a five-fold increase in agonist sensitivity.
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This polymorphism has not, however, consistently been found to be associated with measures of body size and fat distribution. 11, 12 On the other hand, the Glu27 allele of the Gln27Glu polymorphism has been more consistently shown to be associated with an increased risk for obesity, 11, [13] [14] [15] [16] higher BMI, 11, 17 larger fat cell size, 11 and increased risk for type 2 diabetes. 16 Functionally, the Glu27 variant has been shown to display a resistance to agonist-induced downregulation both in vitro 18 and in vivo. 19 This polymorphism may also have implication in the development of insulin resistance, as it has also been shown to be associated with 2 h postload plasma glucose concentration, in addition to sagittal addominal diameter and BMI, in a population-based study in Spain. 20 There are a number of studies, however, that have not observed an association between the Gln27Glu polymorphism and measures of body size or insulin measures. [21] [22] [23] [24] Effect modification by gender and age has been examined in a few instances. Hellstrom et al 14 observed a higher frequency of the Glu27 allele in obese (BMI 427 kg/m 2 ) females vs nonobese females in a Swedish population-based case-control study. They did not however observe the same association in males. This same allele was found to be positively associated with risk of abdominal obesity, as defined by the combination of BMI430 kg/m 2 and WHR40.85, 13 but only in males in a study of Spanish subjects. In this study, male carriers of the 27Glu allele had a 10-fold higher risk of abdominal obesity (OR ¼ 10.31, 95% CI: 1.37-76.8), while female carriers showed no evidence of increased risk (OR ¼ 1.10, 95% CI: 0.60-2.03). Differential effects of Gln27Glu-Arg16Gly haplotypes on glycemia and BMI were observed in younger (o50 y of age) vs older subjects from Northern Italy. 25 The Gly16Glu27 haplotype was associated with higher BMI and lower glycemia in younger subjects but with lower BMI and higher glycemia in older subjects. The P-value for statistical interaction was only marginally significant, however. Research investigating the relationship between ADRB2 and more direct measures of fat deposition, such as computed tomography (CT)-assessed visceral and subcutaneous fat mass, however, has been limited. A small twin study 26 and one report from the HERITAGE study 27 have provided some evidence of an effect of this gene on regional fat distribution. Both of these studies were interventional; however, with the first examining response to overfeeding and the second assessing response to endurance training. A second report from the HERITAGE study did not find an association between either Arg16Gly or Gln27Glu and CTquantified measures of regional fat distribution, although they did report gender-specific interactions between ADRB2 variant genotypes and obesity (defined as BMIZ30 kg/m 2 ) on total fat mass. 12 In order to further investigate the relationship between ADRB2 and a direct assessment of fat deposition, we examined the Arg16Gly and Gln27Glu polymorphisms for association with measures of adiposity and fat deposition, including visceral and subcutaneous adipose tissue quantified by CT, in the IRAS Family Study, a study of African American (AA) and Hispanic American (HA) families from three regions of the US. Furthermore, we explored whether the relationships between these measures and ADRB2 differ according to gender and/or ethnicity.
Research design and methods

IRAS family study
The IRAS Family Study design, recruitment and phenotyping have been described in detail. 28 [29] [30] [31] Baseline examination included measures of BMI, calculated waist to hip ratio (WHR), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and calculated VAT/SAT ratio (VSR). Studies were conducted using protocols approved by the human subjects committees at each participating institution. Fasting glucose levels and S I (as measured by FSIGT) were also obtained at this time.
Abdominal fat mass was measured at the L2/L3 and L4/L5 vertebral region by CT under a common protocol at each of the three sites. Scans were read centrally at the University of Colorado Health Sciences Center, Department of Radiology, for VAT and SAT. Bowel fat was subtracted out from the VAT. The L4/L5 measures were used in these analyses. A small number of participants were missing the L4/L5 data but had L2/L3 data. For these participants, we imputed the L4/L5 data from the L2/L3 data using a simple linear model.
Height and weight were measured to the nearest 0.5 cm and 0.1 kg, respectively. BMI was calculated as weight/ height 2 (kg/m 2 ) and was used as an estimate of overall adiposity. 
Statistical analysis Preliminary analysis. Both the Arg16Gly and Gln27Glu
SNPs were examined for Mendelian inconsistencies using PEDCHECK. 33 Any genotypes inconsistent with Mendelian inheritance were converted to missing. We computed the maximum-likelihood estimates of allele frequencies using the largest set of unrelated individuals and tested these estimates for departures from Hardy-Weinberg proportions.
We estimated the level of linkage disequilibrium between the two SNPs using the classic measure of linkage disequilibriumD D, 34 which measures the magnitude of the deviation of the haplotypes from their expected values under linkage equilibrium. We also calculated the normalized estimate of linkage disequilibriumD D 0 , by dividingD D by its maximum possible value as determined by the two markers' estimated allele frequencies. Thus,D D estimates the magnitude of linkage disequilibrium andD D 0 estimates the signed proportion of the maximal valueD D could obtain conditional on allele frequencies.
Genotypic association. To test for an association between each SNP and each trait (BMI, WHR, SAT, VAT, VSR), we computed a series of generalized estimating equations 35 using SAS software (SAS Institute, Cary, NC, USA). We accounted for the familial correlation using a sandwich estimator of the variance and exchangeable correlation. When necessary, quantitative traits were transformed to best approximate the distributional assumptions of the test (ie link function) and to minimize heterogeneity of variance. Specifically, BMI and VSR were natural logarithm transformed, and VAT and SAT were square root transformed. We computed four tests of association for each SNP and trait combination. Specifically, we computed the two degree-of-freedom test of genotypic association and the three individual contrasts defined by three a priori genetic models (ie dominant, additive, recessive). Tests were computed making two levels of adjustment for covariates: (1) adjusting for age, gender, and recruitment site (Los Angeles, CA, USA; San Antonio, TX, USA; and San Luis Valley, CO, USA); and (2) adjusting for age, gender, recruitment site, and body mass index. In order to investigate whether relationships between ADRB2 polymorphisms and outcomes were consistent across recruitment site and for males vs females, analyses were repeated stratifying by site and by gender, respectively.
Haplotype analysis. To test for a haplotypic association between these traits and the ADRB2 polymorphisms, a weighted GEE1 analysis was computed as above with the weights being the probability for each possible haplogenotype for an individual. Specifically, we computed the expectation-maximization (EM) algorithm estimates for haplotype frequencies from the family data using the software ZAPLO. 36 To reduce the complexity of the problem, ZAPLO assumes Hardy-Weinberg equilibrium and zero recombination events between markers. Using the EM-based haplotype frequency estimates, ZAPLO outputs all possible haplo-genotypes (ie haplotype combinations) for each individual. These data are input into PROFILE 37 to compute the joint probability distribution for the haplotypes of the individuals within the pedigree. This joint probability distribution is then used to estimate the probability of each haplotype pair combination (haplogenotype) possible for each individual, conditional on the family data and assuming Hardy-Weinberg equilibrium. Each individual enters into the GEE1 analysis once for each haplo-genotype possibility, weighted by the estimated haplo-genotype probability. Thus, the weight for each individual sums to one. The weighted GEE1 analyses were completed as above using the same transformations and sandwich estimator of the variance to account for familial correlation. For each site, we computed nine (3 Â 3) tests of haplotype-based association corresponding to the combination of the three observed haplotypes (the Gly16-Glu27 haplotype was not observed with any frequency in any site) and the three previously described a priori genetic models.
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Results
This study sample consisted of 992 individuals from 63 families who participated in the clinical phenotyping examination and were genotyped for the Arg16Gly and Gln27Glu polymorphisms. In all, 57% of the sample that was genotyped for these polymorphisms was female and 15% had been diagnosed with type 2 diabetes mellitus. The mean age was 42.7714.6 (range 18-81) y. Of the sample, 72% was HA (San Antonio and San Luis Valley pedigrees) and 28% was AA (Los Angeles pedigrees). L4/L5 data were missing for n ¼ 44 participants, therefore VAT, SAT, and VSR were missing for these individuals. S I was available for n ¼ 818 participants. Phenotypic characteristics by recruitment site are displayed in Table 1 . Statistically significant differences across study sites were observed for BMI (P ¼ 0.009), WHR (Po0.0001 in men), HDL (P ¼ 0.0002), VAT (Po0.0001) and VSR (Po0.0001). The San Antonio Hispanic sample was characterized by higher mean BMI, WHR, VAT, VSR, and lower mean HDL cholesterol. Differences in allele frequencies according to ethnicity and region, particularly for the Arg16Gly polymorphism, were also observed. The Arg16 allele of the Arg16Gly polymorphism was most frequent in the Hispanic families from the San Luis Valley, with a frequency of 64%. The frequency of this allele was 55% in the Hispanic families from San Antonio and 45% in the AA families. The Gln27 allele of the Gln27Gln polymorphism was most frequent in the AA families, with a frequency of 83%. It was less frequent in the HA families, with the Gln27 allele having a frequency in the San Luis Valley and San Antonio families of 77 and 73%, respectively. None of the individual, site-specific tests for departure from Hardy-Weinberg equilibrium for the Arg16Gly and Gln27Glu polymorphisms were statistically significant. For each of the sites, the two polymorphisms were found to be in strong linkage disequilibrium (D 0 ¼ 1.00 for all sites). Specifically, the frequency of the Gly16Glu27 haplotype was estimated to be zero in all three populations.
While we observed statistical differences across study sites with respect to ADRB2 allele frequencies and several of the outcomes, no statistically significant interaction effect between study site and genotype effects was observed. This suggests that the relationship between genotype and the outcomes did not differ statistically across site and that adjustment for study site main effects in the site-combined analyses was a reasonable approach in order to address potential population stratification.
The Gln27Glu polymorphism was associated with all of the measures of total and central obesity, with the exception of SAT, both before and after adjustment for BMI ( Table 2 ). In the entire sample, the Glu27 allele was associated with larger BMI (P ¼ 0.025), WHR (Po0.0001), VAT (Po0.0001) and VSR (P ¼ 0.020). Estimated genotypic means of these measures suggested a recessive mode of genetic inheritance (Glu27Glu vs Gln27Gln or Gln27Glu) for these traits. P-values for this effect tended to be similar or more statistically significant than the P-values from the two degree-of-freedom general association tests for these four measures ( Table 2) .
The site-specific Gln27Glu analyses were relatively consistent with the entire-sample analysis for VAT and VSR (data not shown). The site-specific analysis of BMI produced evidence of a general association with Glu27Glu genotype in the AAs (P ¼ 0.014) and HAs from San Luis Valley (Po0.001), but not for the HAs from San Antonio (P ¼ 0.979). For WHR, site-specific results were consistent with a recessive model for the Glu27 allele for the two HA sites (San Luis Valley: P ¼ 0.034; San Antonio: P ¼ 0.026), but Adipose tissue and the beta-2 adrenergic receptor LA Lange et al not for the AA site (P ¼ 0.880). The general test of association in the AAs was significant (P ¼ 0.043), however, for WHR. In the analysis of the entire sample, the Arg16Gly polymorphism was not associated with any of the measures of adiposity or fat deposition ( Table 3 ). The site-specific analysis of Arg16Gly yielded similar results, although there was evidence that the Arg16 allele was positively associated with increased SAT for Hispanics in the San Luis Valley (P ¼ 0.027 for general association; P ¼ 0.009 for an additive effect).
The gender-stratified analyses for both the Arg16Gly and Gln27Glu polymorphisms were consistent with the combined analysis and were not suggestive of a gender-by-gene interaction effect (results not shown). The best results from the haplotype-based association tests were nearly identical to the best results obtained from the Gln27Glu polymorphism (data not shown). The similarities between the haplotype and Gln27Glu polymorphism results are explained by the observed absence of the Gly16Glu27 haplotype in each of the site-specific samples. Given the absence of the Gly16-Glu27 haplotype, haplotype tests over the three a priori genetic models involving the Arg16Glu27 haplotype were nearly identical to the congruous tests involving the Glu allele of the Gln27Glu polymorphism.
Discussion
Our results support an association between the Gln27Glu polymorphism and several of the measures of fat deposition and body size, particularly visceral adiposity and visceral-tosubcutaneous ratio. Statistically significant higher mean VAT and VSR were observed in the combined sample, both before and after additional adjustment for BMI. These associations were also characterized by a relative degree of consistency across sites for evidence of a recessive Glu27 allele effect. In the site-specific analyses, VAT was highly statistically significant for the SLV Hispanic sample (Po0.0001) and marginally significant (P ¼ 0.063) for the LA AA sample. While it was not statistically significant in the SA Hispanic sample (P ¼ 0.206 for the recessive model), the genotypic means were consistent with a trend for higher mean VAT in the Glu27 homozygotes. In addition, when additional adjustment was made for BMI, the least-square adjusted means were consistent with higher VAT in the Glu27 homozygotes and the recessive model reached marginal statistical significance in this sample (P ¼ 0.062). Adjustment for BMI did not alter the statistical significance for Gln27Glu in the SLV Hispanic sample. This adjustment, however, did cause a loss of significance in the LA sample, however, there was a small number of Glu27 homozygotes (n ¼ 10) in this Site-specific tests of genotype effect were adjusted by age and gender. Site-combined tests were additionally adjusted by study site and only performed if site-bygenotype interaction was not statistically significant. a n ¼ 44 participants were missing data for these measures.
Adipose tissue and the beta-2 adrenergic receptor LA Lange et al sample. Adjustment for BMI resulted in a higher degree of statistical significance for VSR on the combined sample (Po0.01), and for the site-specific LA sample. The level of statistical significance did not noticeably change for VSR in the site-specific SA and SLV samples. These results suggest that individuals with the Glu27Glu genotype are more likely to have greater fat deposition in the abdominal area than either heterozygotes or homozygotes for the Gln27 allele. The fact that genotype tended to remain statistically significant even after adjustment for BMI suggests that ADRB2 may influence adipose tissue deposition through a metabolic mechanism that is independent of overall body size. The Glu27Glu genotype was also found to be associated with higher BMI and VAT in the combined analysis, but sitespecific analyses were not entirely consistent. There was no statistical evidence for an association with BMI in the HA families from San Antonio or for WHR in the AA families, although the genotypic means for WHR in the AAs were consistent with higher values associated with the Glu27 allele. The lack of association for BMI observed in the San Antonio families could be related to the fact that this population is characterized by a significantly higher mean BMI, possibly related to environmental factors specific to this Hispanic population. A strong environmental influence could decrease the power to detect genetic effects. With the exception of BMI, a tendency was observed for higher mean values of body size and adipose tissue distribution measures in the Glu27Glu homozygotes for this population.
Conversely, we did not observe consistent evidence for an association between the Gln27Glu polymorphism and SAT, either before or after adjustment for BMI. In a single sitespecific analysis (San Luis Valley HAs), we did observe a positive association between Glu27Glu genotype and SAT, but only with adjustment for BMI (P ¼ 0.03 for general test of association; P ¼ 0.009 for additive model).
The Arg16Gly polymorphism was not found to be associated with any of the measures of adiposity in the combined or the site-specific analysis. Our best haplotypebased association results for the Glu27Glu and the Arg16Gly polymorphisms were nearly identical to the best results obtained when analyzing Glu27Glu alone. Together, these results suggest that genotype information from the Arg16Gly polymorphism does not provide any additional predictive value in measurements of adipose tissue deposition in our samples.
Our results are consistent with a number of other studies in finding the Glu27 variant of the Gln27Glu polymorphism Site-specific tests of genotype effect were adjusted by age, gender, and BMI (except in the model for BMI). Site-combined tests were additionally adjusted by study site. a n ¼ 44 participants were missing data for these measures.
Adipose tissue and the beta-2 adrenergic receptor LA Lange et al to be positively associated with obesity-related phenotypes. Large et al 11 reported a positive association between this variant and obesity defined by medical referral for uncomplicated obesity, BMI, WHR, total body fat and fat cell volume, while finding no such association with the Arg16-Gly polymorphism. This study, however, did not have measures of regional fat distribution. Ironically, the Gln27Glu polymorphism was not found to be associated with ADRB2 protein function in adipose tissue samples in this study, whereas the Arg16Gly polymorphism was. A recent study of a population-based sample of 666 Caucasians from Spain also reported evidence for higher abdominal obesity in homozygotes for the Glu27 allele, as measured by mean sagittal abdominal diameter (Po0.04), although it was only observed in men. 20 Our results are not as consistent with the limited number of studies examining CT-quantified fat distribution. In a small study of 12 monozygotic male twin pairs, the Glu27 allele was associated with a greater increase in total CTmeasured subcutaneous fat and total weight gain in response to long-term overfeeding (Po0.005). 26 Two recent reports addressing the relationship between ADRB2 and fat measures quantified by CT from the HERITAGE study have produced evidence for association, but only in subgroups. The first 27 examined the Arg16Gly, but not the Gln27Glu, polymorphism with respect to response to endurance training in AA and Caucasian subjects, reporting no significant main-effect association between this polymorphism and change in CTmeasured visceral fat area, although they did report an interaction between Arg16Gly and a polymorphism in the beta-3 adrenergic receptor on change in total abdominal fat area. In the second study 12 the Gln27Glu polymorphism was found to be associated with baseline total fat mass in obese men, with higher mean fat mass associated with the Gln27 allele (P ¼ 0.0001 for genotype-by-obesity interaction). This polymorphism was not found to be associated in either nonobese men or in women (obese or nonobese). The Arg16Gly variant was, however, found to be associated with fat mass in obese women, with the Gly16Gly homozygotes having the lowest fat mass (P ¼ 0.01 for genotype-by-obesity interaction). Neither variant was found to be associated with measures of visceral vs subcutaneous fat distribution in their study. These findings may have important implications for the risk of insulin resistance, diabetes and cardiovascular disease. Visceral fat, specifically, is important in the pathophysiology of these conditions, as indicated by the following. First, the vasculature of visceral fat is unique in that it is connected via the portal venous system to the liver, allowing direct free fatty acid flux into the liver. This can lead to suppression of 41 This results in higher systemic and portal free fatty acid concentrations in individuals with larger amounts of VAT. Moreover, visceral adipocytes differ from subcutaneous adipocytes in their release of secretory proteins. In at least one study, visceral fat expressed and released more plasminogen activator inhibitor-1 (PAI-1), an inhibitor of fibrinolysis, compared to subcutaneous fat. 42 Expression of angiotensinogen, a potential regulator of blood pressure, is also higher in visceral adipose tissue. 43 Finally, proteins that are potentially protective for diabetes and cardiovascular disease (adiponectin, cholesterol ester transfer protein, leptin, glycogen synthase and peroxisome proliferator activated receptor-gamma) show lower expression levels in visceral than subcutaneous adipocytes.
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Interestingly, we observed some evidence for an association between both ADRB2 polymorphisms and measures related to insulin sensitivity (see Table 4 ). In a combined analysis adjusting for study site, age and gender, both S I (P ¼ 0.006) and fasting glucose (P ¼ 0.011) were found to be significantly associated with the Gln27Glu polymorphism. The genotypic means and model results, however, were suggestive of a dominant mode of inheritance (Glu27Glu or Gln27Glu vs Gln27Gln) rather than the recessive model suggested with the adiposity measures. When additional adjustment was made for BMI and VAT, this association remained significant for S I (P ¼ 0.039) but not for fasting glucose (P ¼ 0.46). In site-specific analysis, the Glu27 allele was associated with lower insulin sensitivity in LA and SLV, but the genotypic means suggest a dominant mode of inheritance for this allele. This association was not observed in the SA Hispanics, although the phenotypic means tended to increase with additional copies of the Glu27 allele. In the site-specific analyses, evidence for an association between fasting glucose and this polymorphism were not consistent. A limited degree of evidence for association was also observed for both S I and fasting glucose with the Arg16Gly polymorphism, but it was also not consistent across sites. The fact that S I remained statistically significantly associated with ADRB2 polymorphisms even after adjustment for BMI and VAT may indicate that there is some independent action of ADRB2 on insulin sensitivity that is not merely a result of its effect on adipose tissue distribution. The results, however, were not quite as strong or consistent as observed for VAT, so it may be that the association with S I is a result of the effects of ADRB2 on adipose cells and that CT-assessed VAT does not fully account for this.
While a number of other studies have provided evidence in support of ADRB2 playing a role in obesity and anthropomorphically measured regional fat distribution, which are both strong risk factors for insulin resistance, diabetes and cardiovascular disease, this is the first large study that we are aware of to report an association between CT-quantified adipose tissue distribution and polymorphisms in this gene. Identification of the specific effect of ADRB2 on adiposity tissue deposition could help shed light on its influence on these diseases.
In conclusion, the present study provides support for a role of the gene coding the beta-2 adrenergic receptor in the deposition of body fat with a high degree of consistency across three subpopulations from the US: AA families from Los Angeles, CA, USA; HA families from San Antonio, TX, USA; and HA families from San Luis Valley, CO, USA. Specifically, this gene appears to be associated with visceral fat deposition rather than subcutaneous fat deposition and is characterized by Glu27 homozygotes of the Gln27Glu polymorphism tending to have higher visceral fat deposition than either heterozygotes or homozygotes for the Gln27 allele. These findings may have important implications for obesity prevention efforts.
